Unknown

Dataset Information

0

In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.


ABSTRACT: The hepatitis C virus (HCV) serine protease is necessary for viral replication and represents a valid target for developing new therapies for HCV infection. Potent and selective inhibitors of this enzyme have been identified and shown to inhibit HCV replication in tissue culture. The optimization of these inhibitors for clinical development would greatly benefit from in vitro systems for the identification and the study of resistant variants. We report the use HCV subgenomic replicons to isolate and characterize mutants resistant to a protease inhibitor. Taking advantage of the replicons' ability to transduce resistance to neomycin, we selected replicons with decreased sensitivity to the inhibitor by culturing the host cells in the presence of the inhibitor and neomycin. The selected replicons replicated to the same extent as those in parental cells. Sequence analysis followed by transfection of replicons containing isolated mutations revealed that resistance was mediated by amino acid substitutions in the protease. These results were confirmed by in vitro experiments with mutant enzymes and by modeling the inhibitor in the three-dimensional structure of the protease.

SUBMITTER: Trozzi C 

PROVIDER: S-EPMC149541 | biostudies-literature | 2003 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.

Trozzi Caterina C   Bartholomew Linda L   Ceccacci Alessandra A   Biasiol Gabriella G   Pacini Laura L   Altamura Sergio S   Narjes Frank F   Muraglia Ester E   Paonessa Giacomo G   Koch Uwe U   De Francesco Raffaele R   Steinkuhler Christian C   Migliaccio Giovanni G  

Journal of virology 20030301 6


The hepatitis C virus (HCV) serine protease is necessary for viral replication and represents a valid target for developing new therapies for HCV infection. Potent and selective inhibitors of this enzyme have been identified and shown to inhibit HCV replication in tissue culture. The optimization of these inhibitors for clinical development would greatly benefit from in vitro systems for the identification and the study of resistant variants. We report the use HCV subgenomic replicons to isolate  ...[more]

Similar Datasets

| S-EPMC305661 | biostudies-literature
| S-EPMC2223918 | biostudies-literature
| S-EPMC11359326 | biostudies-literature
| S-EPMC2798386 | biostudies-literature
| S-EPMC4946931 | biostudies-literature
| S-EPMC6772116 | biostudies-literature
| S-EPMC3088261 | biostudies-literature
| S-EPMC3058531 | biostudies-literature
| S-EPMC4278837 | biostudies-literature
| S-EPMC2415816 | biostudies-literature